3- (5- chloro- 2- furoyl)- 3,7- diazabicyclo(3.3.0)octane

03/01/2014 - "While the present study does not support the therapeutic utility of AZD1446 in ADHD, its potential pro-cognitive effects remain to be explored in other neuropsychiatric disorders."
03/01/2014 - "The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AZD1446 in adults with ADHD treated for 2 weeks. "
03/01/2014 - "AZD1446 was well tolerated, but did not significantly improve ADHD symptoms after 2 weeks of treatment compared to placebo. "
03/01/2014 - "AZD1446 is a selective α4β2* nicotinic acetylcholine receptor agonist with potential effect on the symptoms of ADHD. "
03/01/2014 - "A randomized, double-blind, placebo-controlled crossover study of α4β 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder."

11/08/2012 - "A novel potent and highly selective α4β2 nAChR agonist 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (56, TC-6683, AZD1446) with favorable pharmaceutical properties and in vivo efficacy in animal models has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions and is currently being progressed to phase 2 clinical trials as a treatment for Alzheimer's disease."

01/01/2014 - "AZD1446 was safe and well tolerated, with nausea, headache and dizziness as the most frequently reported adverse events. "

01/01/2014 - "AZD1446 was safe and well tolerated, with nausea, headache and dizziness as the most frequently reported adverse events. "

01/01/2017 - "Evaluation of AZD1446 as a Therapeutic in DYT1 Dystonia."
01/01/2017 - "We used a DYT1 ∆GAG knock-in mouse model (DYT1 KI) to investigate whether nicotine and/or a non-desensitizing nicotinic agonist, AZD1446, would increase DA output in DYT1 dystonia. "